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ment option for a disease where few options existed. Based on studies reviewed, 
sildenafil and NAC treatments did not slow disease progression as measured by 
change in percent FVC and their use in IPF should be limited.
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Objectives: Clinical trials of chronic obstructive pulmonary disease (COPD), a pro-
gressive disease with a substantial economic burden, primarily assess exacerbation 
rates based on health resource utilization (HRU), leading payers to focus on this 
endpoint as a cost driver. The drug approval process often requires documenta-
tion of clinically relevant improvements in measures such as forced expiratory 
volume in one second (FEV1); however, their link to longer-term outcomes, such as 
exacerbations and HRU are not known. We conducted a systematic review of the 
published literature to evaluate the linkage. MethOds: We searched MEDLINE- and 
Embase-indexed English-language publications from 2002 through October 1, 2014 
for randomized controlled trials with ≥ 20 adult patients with COPD. Included trials 
described changes in FEV1or St. George’s Respiratory Questionnaire (SGRQ), as well 
as exacerbations or HRU. Results: We identified 13 trials among 1,196 publications 
reporting changes in SGRQ or FEV1 and rate of exacerbation and hospitalization. 
We combined FEV1 pre-bronchodilator values with FEV1trough values given the 
similarity of these variables. Based on the MCID value for SGRQ of 4 units, exacerba-
tions ranged from 0.414 to 5.61/person-year among those not reaching SGRQ MCID, 
compared with a range of 0.42-1.07/person-year among those reaching SGRQ MCID. 
Using a minimal clinically important difference (MCID) value for FEV1 of 100mL, the 
exacerbation rate ranged from 0.414 to 5.61/person-year among those not reaching 
FEV1 MCID, compared to 0.69 to 1.02/person-year among those reaching FEV1MCID. 
The annual hospitalization rate due to exacerbations ranged from 0.02-0.7/per-
son-year among those not reaching SGRQ MCID, and from 0.03-0.16/person-year 
among those reaching SGRQ MCID. Annual hospitalization rates due to exacerba-
tions ranged from 0.02-0.7/person-year among those not reaching FEV1 MCID, com-
pared to 0.05-0.16/person-year among those reaching FEV1MCID. cOnclusiOns: 
Preliminary results suggest a relationship between clinically meaningful improve-
ments in bronchodilation and patient-reported outcomes and annualized exacerba-
tions and hospitalizations.
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Objectives: To describe the use of heliox therapy in a case series of patients 
admitted to emergency department or/and intensive care unit of children hospital 
“Napoleon Franco Pareja” in Cartagena, Colombia. MethOds: We described the 
clinical features and results of heliox therapy in a series of patients admitted in 
emergency room and/or intensive care unit. For qualitative variables proportions 
were used and for numeric variables were analyzed with averages and meas-
ures of dispersion. We compared the differences in categorical variables using 
the chi-square or Fisher exact test. The aplicative Epidat 3.1 was used for data 
analysis Results: Fifty two patients were included, of whom 59.6% were male. 
The mean age was 21.2 months (SD: 25.6). The two most frequent diagnoses were 
status asthmaticus (32.7%) and acute bronchiolitis (26.9%). Mortality was 5.8%. 
Success of heliox therapy was 76.9%. The route of administration was not related 
to the type of response. The duration of heliox therapy averaged 5.9 hours (SD 
4.1) in patients who did not respond favorably and 8.0 hours (SD 5.6) in those 
who responded to heliox. Fifty percent off patients did not need endotracheal 
intubation and all responded favorably to heliox therapy. cOnclusiOns: A 
high success rate with heliox therapy was found in this case series. Its use is 
recommended as an adjunct therapy in the management of acute respiratory 
insufficiency.
PRS8
ReaL-woRLd obSeRvatIonaL Study of aSSocIatIon between StatIn 
medIcatIonS and coPd-SPecIfIc outcomeS
Ajmera M.R.1, Sambamoorthi U.2, Rust G.3, Pan X.4, Tworek C.2, Metzger A.2
1RTI Health Solutions, RTP, NC, USA, 2West Virginia University, Morgantown, WV, USA, 
3Morehouse School of Medicine, Atlanta, GA, USA, 4Evidera LLC, Lexington, MA, USA
Objectives: Disease modifying drugs are not yet available for the management 
of individuals with Chronic Obstructive Pulmonary Disease (COPD). Statin therapy, 
due to its anti-inflammatory properties is under consideration for the manage-
ment of COPD. This study examined the relationship between statin therapy and 
COPD-specific outcomes. MethOds: Retrospective longitudinal dynamic cohort 
design using Medicaid claims data from multiple years (2005-2008) was utilized. 
Statin therapy was identified from the prescription drug file using the National 
Drug Codes (NDC). COPD-specific outcomes such as hospitalizations, emergency 
room and outpatient visits were identified based on a primary diagnosis of COPD. 
Multivariable logistic regressions with Inverse Probability Treatment Weights (IPTW) 
were used to examine the relationship between statin therapy and COPD-specific 
outcomes. The relationship between multimorbidity, statin medications and COPD-
specific outcomes was tested using an interaction term. Secondary analyses with 
Objectives: Pneumonia-related 30-day readmission rates are publically reported 
as part of the Hospital Readmissions Reduction Program to improve quality of 
care for Medicare beneficiaries. We estimated the impact of pneumonia on inpa-
tient mortality and 30-day readmission rates in mechanically ventilated (MV) 
patients. MethOds: We performed a cohort study of MV patients using the 
Premier Inpatient database (July 2012 to June 2013). Patients on MV for > = 1 day 
were included and classified based on those with a pneumonia-related diagno-
sis code and those without. Patients were followed for the entire period of their 
hospitalization. Inpatient mortality and rates of readmission for the thirty days 
post discharge were compared between the two groups using generalized linear 
models (GLMs). We estimated both outcomes using the binomial distribution, 
controlling for patient demographics, 3M™ All Patient Refined Diagnosis Related 
Group Severity and Mortality indices, and hospital characteristics. Results: A 
total of 65,246 patients met criteria, of which 15,421 (23.6%) carried a pneumonia 
diagnosis. Pneumonia patients were older (64.2 vs 58.0 years, p< 0.0001), more 
likely to be male (46.8% vs 45.3%, p= 0.0012), white (72.4% vs 66.9%, p< 0.0001), and 
on public insurance (75.6% vs 65.2%, p< 0.0001). Comparing outcomes, pneumo-
nia patients experienced significantly higher rates of mortality (25.5% vs. 18.1%, 
p< 0.0001) and 30-day readmission (15.3% vs. 12.9%, p< 0.0001). After adjustment 
for patient and institutional factors in the GLM regressions the risk of both out-
comes remained statistically significant with odds ratios of 1.05 (95% CI: 1.01 to 
1.10) for mortality and 1.11 (95% CI: 1.05 to 1.17) for 30-day readmission (p= 0.024 
and 0.0002, respectively). cOnclusiOns: Pneumonia in MV patients increases the 
risk of mortality and 30-day readmissions. With penalties as high as 3% across all 
Medicare payments for readmission, efforts should continue to carefully evaluate 
the care of mechanically ventilated patients with pneumonia.
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Objectives: Multimorbidity is highly prevalent among individuals with Chronic 
Obstructive Pulmonary Disease (COPD). The association between multimorbidity and 
COPD medication management is not well researched. This study sought to examine 
the association between multimorbidity and receipt of COPD medications among 
Medicaid beneficiaries with newly diagnosed COPD. MethOds: Retrospective lon-
gitudinal dynamic cohort design was used and data were extracted from multiple 
years (2005-2008) of Medicaid Analytic eXtract (MAX) files. Medicaid beneficiaries with 
newly diagnosed COPD (N = 19,060) were identified using International Classification 
of Diseases Codes (ICD-9-CM) codes for COPD. ICD-9-CM codes for commonly co-
occurring conditions with COPD were used to create multimorbidity variable. These 
conditions included arthritis, cardiovascular diseases (CVD), depression, diabetes, 
hypertension, hyperlipidemia and osteoporosis. Medicaid beneficiaries with newly 
diagnosed COPD were categorized into following multimorbidity categories: 1) physi-
cal multimorbidity only; 2) mental multimorbidity only; 3) both physical and mental 
multimorbidity and 4) no multimorbidity. Receipt of COPD medications (short-act-
ing, long-acting bronchodilators and inhaled corticosteroids) was identified using 
National Drug Codes. Bivariate relationships between multimorbidity and COPD 
medication receipt were tested using chi-square test of independence. The associa-
tions between multimorbidity and COPD medication receipt were analyzed with logis-
tic and multinomial logistic regressions. Results: Among Medicaid beneficiaries 
with newly diagnosed COPD, 74.9% had at least one co-occurring chronic condition. 
After controlling for patient characteristics, adults with multimorbidity were less 
likely to receive COPD medications compared to those without any multimorbidity. 
For example those with physical multimorbidity were less likely to receive short-
acting bronchodilators (AOR: 0.82; 95% CI: 0.75, 0.89), long-acting bronchodilators 
(AOR: 0.86; 95% CI: 0.79, 0.93) and inhaled corticosteroids (AOR: 0.81; 95% CI: 0.75, 0.88) 
compared to those with no inflammation-related multimorbidity. cOnclusiOns: 
Prevalence of multimorbidity is very high among Medicaid beneficiaries with newly 
diagnosed COPD. Our study findings suggest poor COPD medication management 
among those with multimorbidity.
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Objectives: Idiopathic pulmonary fibrosis (IPF) is a rare, progressive form of 
fibrosing interstitial pneumonia which results in loss of lung function and pre-
mature mortality. The FDA first approved treatments for IPF in late 2014. The aim 
of this systematic review and network meta-analysis (NMA) is to perform a mixed 
treatment comparison of the efficacy of available pharmacologic treatments for 
IPF. MethOds: Medline, EMBASE, CENTRAL, and PROSPERO were searched for ran-
domized clinical trials in patients with IPF and supplemented with hand searches. 
Only randomized trials consisting exclusively of IPF patients were included. All stud-
ies were independently abstracted by two analysts. The primary outcome of interest 
was the standardized mean difference between treatment and control of change in 
percent predicted forced vital capacity (FVC) from baseline to one year. Results: 
Literature review identified 1,191 records of which 36 met our inclusion criteria. 
Fixed effects pairwise comparisons of the standardized mean difference (SMD) of 
intervention versus placebo suggested better performance of nintendanib rela-
tive to other treatments with a 4.9% (95%CI: 3.8-6.0) standardized improvement 
relative to placebo in %FVC . This falls comfortably within the range of minimal 
clinically important difference for this endpoint as measured by other authors. 
The data structure for pirfenidone did not allow for comparison of %FVC. Sildenafil, 
N-acetylcysteine (NAC), and azathioprine did not show statistically significant 
improvement relative to placebo. cOnclusiOns: Nintenadib offers a new treat-
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Objectives: To compare the rate of inpatient admissions of pediatric patients with 
acute asthma that came through the emergency department (ED) visits and mean 
charges per ED visit between Medicaid patients and privately insured patients. To 
identify factors associated with hospital admissions through the ED among pediatric 
patients with asthma. MethOds: A retrospective analysis using 2010-2011 National 
Emergency Department Sample (NEDS), the largest all-payer hospital based ED data-
base in the United States (US), was conducted. All ED visits with a primary diag-
nosis of acute asthma for patients aged 2-17 years were identified using ICD-9-CM 
codes of 493.XX. ED visits with unknown destination were excluded. Multivariable 
logistic regression and Generalized Linear Mixed Model were used to compare the 
rate of hospital admissions through the ED and mean ED charges between asthma 
children with Medicaid vs private insurance. Results: A total of 110,964 pediat-
ric asthma related ED visits from 1,713 US EDs was identified (Medicaid patients: 
n= 69,410 (63%), mean age= 7yrs, 39.86% female; Private insured patients: n= 41,554 
(37%), mean age= 7yrs, 39.79% female). Of these occurrences, 96,307 (87%) were 
discharged and 14,657 (13%) were admitted to hospital after ED visits. After adjusting 
for demographic and clinical factors, privately insurance patients were 12% more 
likely to be admitted to hospital after ED visits compared to Medicaid patients. (Odds 
ratio= 1.12, [95% confidence interval: 1.13-1.32]). The mean charge per ED visit for 
Medicaid insured patients was $1,330, compared to $1,380 among private insured 
patients (p< 0.01). Other factors associated with hospital admissions through ED 
were younger age, severity, weekday visits, and urban-rural location of patient’s 
residence. cOnclusiOns: Compared to asthma children with Medicaid, privately 
insured pediatric patients had increased hospital admissions through ED and ED 
charges. In addition to insurance type, factors relating to severity and hospital char-
acteristics were related to hospital admissions through the ED.
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Objectives: To examine the mortality and rehospitalization rates among hospi-
talized U.S. Medicare patients diagnosed with pneumonia. MethOds: Using U.S. 
Medicare data, 30-day and 1-year mortality rates as well as rehospitalization rates 
were calculated for patients with a primary diagnosis of pneumonia (International 
Classification of Diseases, 9th Revision, Clinical Modification [ICD-9-CM] codes 
480.0-483.99 or 485-487) or a secondary discharge diagnosis of pneumonia with 
a primary diagnosis of respiratory failure (ICD-9-CM code 518.81) or sepsis (038.
xx). Patients with continuous enrollment in a fee-for-service Medicare health 
plan throughout the calendar year, and at least 2 years prior, were included in 
the study. Age- and gender-adjusted readmission rates were calculated by direct 
standardization of the U.S. population age ≥ 65 years in 2010 using gender-specific 
age groups. Results: The 30-day and 1-year mortality rates increased by 5.9% (17 to 
18 per 1,000 person-years) and 13.2% (38 to 43 per 1,000 person-years), respectively, 
from 2008 to 2012. The overall adjusted readmission rates were 3.82% in 2008, 3.93% 
in 2009, 3.98% in 2010 and 2011, and 3.17% in 2012. Men had higher readmission rates 
than women for all study years except 2011. Patients age 65-69 years had the highest 
readmission rates in 2008 (4.47%), 2009 (4.59%) and 2011 (4.77%). In 2010, patients age 
70-74 years (4.41%), and in 2012, patients who were age 75-79 years (3.73%) had the 
highest readmission rates. Black patients had the highest readmission rates in 2008 
(5.08%), North American Natives in 2009 (4.86%), other race in 2010 (5.87%), Hispanics 
in 2011 (5.70%) and North American Natives in 2012 (7.11%). cOnclusiOns: Among 
U.S. Medicare beneficiaries diagnosed with pneumonia, mortality rates were higher 
from 2009 to 2012 than in 2008. Overall, hospital readmission rates were lower in 
2012 than 2008, after adjusting for age and gender. Readmission rates varied across 
race and age groups.
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Objectives: Hospital readmissions among patients with COPD have contributed 
a considerable burden to the healthcare system as measured by increased hospital 
stays and healthcare expenditures. The objective of this study is to estimate the 
factors influencing 30-day readmissions among patients with COPD. MethOds: A 
multivariable logit regression was conducted for patients with COPD [ICD 9 code(s) 
491, 492 or 496] discharged to home or other facilities, utilizing the 2012 Truven 
MarketScan dataset (un-weighted n= 21,771). The outcome variable was a dichoto-
mous 30-day readmission, considering any type of readmission. The covariates 
included demographic variables, characteristics of index hospitalization and risk 
factors including prior hospitalization and comorbidities. Results: The 30-day 
readmission rate among patients with COPD was 6.8%. Elderly patients (65+) 
were 77% [Odd ratio (OR)= 0.23, p= 0.001] less likely to be readmitted than younger 
cohort (aged 18-34). Male patients were 19% (OR= 1.19, p= 0.010) more likely to be 
readmitted than female patients. Patients with HMO, POS and Comprehensive 
insurances were 135% more (OR= 2.35, p< 0.001), 28% less (OR= 0.72, p< 0.029) and 
70% less (OR= 0.30, p< 0.001) likely to be readmitted than those with PPO. Patients 
discharged to facilities, and to home under care were 162% (OR= 2.62, p< 0.001) 
and 25% (OR= 1.25, p= 0.028) more likely to be readmitted than those discharged 
to home. Patients with asphyxia and respiratory arrest, anemia, and tobacco use 
were more likely to be readmitted than those without by 28% (OR= 1.28, p= 0.016), 
22% (OR= 1.22, p= 0.023) and 20% (OR= 1.20, p= 0.020), respectively. In addition, an 
increase of hospitalizations in the previous year contributed to a 0.75% probability 
increase of 30-day readmissions (p< 0.001). A one-day extended index hospital 
duration of stain therapy were also conducted. All analyses will be conducted using 
SAS version 9.3. Results: The study included 19,060 Medicaid beneficiaries with 
newly-diagnosed COPD, out of whom 30.3% beneficiaries received statins during the 
1-year baseline period. Compared to adults without statin therapy, those with statin 
therapy had significantly lower rates of COPD-specific hospitalizations (4.7% vs. 
5.2%; p< 0.05), emergency room visits (13.4% vs. 15.4%; p< 0.001) and outpatient visits 
(41.4% vs. 44.7%; p< 0.001). Even after adjusting for observed selection bias with IPTW 
technique, adults with statin therapy were less likely to have COPD-specific hospital-
izations (AOR: 0.76; 95% CI: 0.66, 0.87), emergency room visits (AOR: 0.81; 95% CI: 0.75, 
0.89) and outpatient visits (AOR: 0.86; 95% CI: 0.80, 0.91) compared to those without 
statin therapy. Adults with multimorbidity and statin therapy were less likely to 
have COPD-specific outcomes. cOnclusiOns: Statin therapy was associated with 
reduction in COPD-specific outcomes. These findings may suggest beneficial effects 
of statin among newly diagnosed COPD patients and warrant further clinical trial 
investigation.
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Objectives: Self-medication in both rural and urban population in Pakistan is 
an increasingly growing concern. Both literate and illiterate people irrespective 
of age and gender practice self-medication, which is in more than 50% of cases 
inappropriate. The aim of this study was to survey over-the-counter availability 
of medicines and self- medication pattern among the rural and urban popula-
tion of Karachi, Pakistan. MethOds: Over 1300 volunteers of ages (between 
20-80 years) and both genders were surveyed for their self-medication pattern. 
Medicines were grouped as antimicrobials and non-antimicrobials. Results: 93% 
of volunteers confirmed the practice of self-medications and the frequency was 
higher in females (57%) as compared to males (43%), and the pattern was same 
in both urban and rural environment. The general symptoms for which medi-
cines were taken included head ache (80%), body pain (67%), fever (40%), disturbed 
bowel (83%) and flu/cough/cold (72%). Among the non-antimicrobial medicines, 
the most frequently used groups were aspirin, paracetamol, chlorpheniramine, 
pseudoephedrine, ibuprofen and metronidazole. 13 % of the individuals confirmed 
adverse effects of the medicines. Among the antimicrobial drugs, only antibiot-
ics were taken, and almost all classes and generations of antibiotics were taken. 
Oral formulations of penicillins, quinolones, and cephalosporins were frequently 
used as compared to other classes of antibiotics. However, not a single example 
of intravenous and intramuscular antibiotics was observed. 43% of the individuals 
confirmed that antibiotics were ineffective in their condition. cOnclusiOns: 
The unregulated over-the-counter availability of medicines and the practice of 
self-medication are increasingly growing threats to the health care system in 
Pakistan. The inappropriate medications not only add to mortality and morbidity, 
but also cause increased cost of treatments. Such habits must be shunned through 
legislation and community awareness.
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Objectives: To measure the effectiveness of adherence interventions for asthma 
controllers on medication adherence and acute hospitalization (emergency 
room [ER] and inpatient) in two Medicaid managed care organizations (MCOs) in 
Southeastern Pennsylvania (SEPA) and Lehigh/Capital-New West Pennsylvania 
(LCNWPA). MethOds: One-year follow-up analysis of prescription and hospitali-
zation member data with prescription fills for asthma controllers from January 1 
to December 31, 2012. Thirty various interventions—categorized as general inter-
ventions (GI) for all subjects and personalized interventions (PI) for higher-risk 
care-managed subjects—were implemented to improve 2013 adherence. Medication 
adherence (proportion of days covered [PDC]; baseline inclusion criterion: 20%–67%) 
and acute hospitalization rates (utilization per thousand members per year) were 
calculated at baseline and at one-year post-intervention. Results: Of 3,589 par-
ticipants (793 LCNWPA; 2,796 SEPA), 767 were PI subjects (196 LCNWPA; 571 SEPA). 
SEPA and LCWPA member profiles were demographically similar to one another, 
except regarding race and ethnicity. The PDC rate improvements for asthma con-
trollers were 4.86% for LCNWPA and 2.95% for SEPA (P< 0.01 for both), accompanied 
by significant reductions in ER visits (−9.2% and −8.2%, respectively; P< 0.01 for 
both); the SEPA cohort also experienced significantly reduced inpatient admissions 
(−21.7%; P= 0.02). Improvements in mean PDC were significantly greater in PI than 
GI subjects (LCNWPA: 11.42% vs. 2.70%, P< 0.01; SEPA: 7.35% vs. 1.82%, P< 0.01), but 
acute hospitalization rates were not statistically lower in PI than GI subjects due to 
selection bias. Subjects demonstrating improvements in 2013 PDC rates displayed 
comparable changes in acute hospitalization rates as their non-improving coun-
terparts. cOnclusiOns: Multifaceted MCO-implemented adherence interven-
tions significantly improved medication adherence rates in Medicaid participants, 
translating into significant reductions in acute hospitalization. These results were 
especially apparent in higher-risk subjects.
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